CN101641369B - Foxp3肽疫苗 - Google Patents

Foxp3肽疫苗 Download PDF

Info

Publication number
CN101641369B
CN101641369B CN200780051977.4A CN200780051977A CN101641369B CN 101641369 B CN101641369 B CN 101641369B CN 200780051977 A CN200780051977 A CN 200780051977A CN 101641369 B CN101641369 B CN 101641369B
Authority
CN
China
Prior art keywords
peptide
foxp3
cell
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780051977.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101641369A (zh
Inventor
角田卓也
大泽龙司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN101641369A publication Critical patent/CN101641369A/zh
Application granted granted Critical
Publication of CN101641369B publication Critical patent/CN101641369B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200780051977.4A 2007-01-03 2007-12-26 Foxp3肽疫苗 Expired - Fee Related CN101641369B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87861507P 2007-01-03 2007-01-03
US60/878,615 2007-01-03
US89647207P 2007-03-22 2007-03-22
US60/896,472 2007-03-22
PCT/JP2007/001466 WO2008081581A1 (en) 2007-01-03 2007-12-26 Foxp3 peptide vaccine

Publications (2)

Publication Number Publication Date
CN101641369A CN101641369A (zh) 2010-02-03
CN101641369B true CN101641369B (zh) 2014-10-22

Family

ID=39588270

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780051977.4A Expired - Fee Related CN101641369B (zh) 2007-01-03 2007-12-26 Foxp3肽疫苗

Country Status (14)

Country Link
US (1) US8563516B2 (cg-RX-API-DMAC10.html)
EP (2) EP2114987A4 (cg-RX-API-DMAC10.html)
JP (1) JP5339375B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090099075A (cg-RX-API-DMAC10.html)
CN (1) CN101641369B (cg-RX-API-DMAC10.html)
AU (1) AU2007340834B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0720794A2 (cg-RX-API-DMAC10.html)
CA (1) CA2674365A1 (cg-RX-API-DMAC10.html)
IL (1) IL199622A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009007261A (cg-RX-API-DMAC10.html)
RU (1) RU2473557C2 (cg-RX-API-DMAC10.html)
SG (1) SG177199A1 (cg-RX-API-DMAC10.html)
TW (1) TWI441648B (cg-RX-API-DMAC10.html)
WO (1) WO2008081581A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050486A2 (en) * 2007-10-19 2009-04-23 The University Of Surrey Peptide manipulators of regulatory t cell activity
CZ2008565A3 (cs) * 2008-09-15 2009-11-18 Vysoká škola chemicko technologická v Praze Príprava monoklonálních protilátek proti FoxP3 proteinu s použitím modifikovaných virum podobných cástic Masonova-Pfizerova opicího viru
KR20110117112A (ko) * 2008-12-24 2011-10-26 온코세라피 사이언스 가부시키가이샤 Ｃ１ｏｒｆ５９ 펩티드 및 이를 포함하는 백신
TWI507204B (zh) * 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
US9458447B2 (en) * 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
CN102603892B (zh) * 2012-02-22 2013-10-30 尉军 一种肿瘤标志物foxp3抗原多肽及应用
US11505599B2 (en) * 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
CN111375055B (zh) * 2020-02-20 2021-09-03 陈宛莎 一种2019-nCoV亚单位疫苗组合物及其免疫方法
CN122438694A (zh) * 2023-12-19 2026-07-21 瑞泽恩制药公司 Foxp3肽及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922436A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses
US7507542B2 (en) 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
EP2267023B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
JP4840866B2 (ja) 2005-01-19 2011-12-21 学校法人慶應義塾 癌ワクチン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GLIBOA ELI等.symposium: advances in immunotherapy targeting immune evasion in cancer immunotherapy.《PROC AMER ASSOC CANCER RES 》.2006,第47卷(第1期),abstract SY04-01 第1357页. *
Smita Nair等.Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity.《Cancer Research》.2007 American Association for Cancer Research,2007,第67卷(第1期),第371-380页. *

Also Published As

Publication number Publication date
EP2114987A1 (en) 2009-11-11
TWI441648B (zh) 2014-06-21
EP2481748A3 (en) 2012-10-24
US8563516B2 (en) 2013-10-22
CN101641369A (zh) 2010-02-03
MX2009007261A (es) 2009-11-11
AU2007340834A1 (en) 2008-07-10
IL199622A0 (en) 2010-04-15
EP2481748A2 (en) 2012-08-01
US20100092501A1 (en) 2010-04-15
RU2009129531A (ru) 2011-02-10
RU2473557C2 (ru) 2013-01-27
TW200835516A (en) 2008-09-01
AU2007340834B2 (en) 2013-02-28
BRPI0720794A2 (pt) 2014-03-11
CA2674365A1 (en) 2008-07-10
JP2010514669A (ja) 2010-05-06
SG177199A1 (en) 2012-01-30
WO2008081581A1 (en) 2008-07-10
JP5339375B2 (ja) 2013-11-13
KR20090099075A (ko) 2009-09-21
EP2114987A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
CN101711280B (zh) Tem8肽和包含tem8肽的疫苗
RU2469044C2 (ru) Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1
CN103351423A (zh) 用于表达肿瘤相关抗原的癌症的肽疫苗
SG193214A1 (en) Inhbb epitope peptides and vaccines containing the same
CN104958753B (zh) Hig2和urlc表位肽及包含它们的疫苗
CN101641369A (zh) Foxp3肽疫苗
RU2496787C2 (ru) Пептиды эпитопов mybl2 и содержащие их вакцины
CN104086625A (zh) Rab6kifl/kif20a表位肽及包含它的疫苗
CN104650183A (zh) Wdrpuh表位肽及包含它的疫苗
HK1174337A (en) Foxp3 peptide vaccine
HK1175197B (en) Tem8 peptides and vaccines comprising the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141022

Termination date: 20151226

EXPY Termination of patent right or utility model